



Astal Laboratories Limited

# STAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: 8-2-351/w/3/4, Road Number 3, Banjara Hills, Hyderabad, Telangana, 500034

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: <https://astallabs.com/>

Date: 27/01/2025

To,  
The Deputy Manager  
Department of Corporate Services  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai- 400001

Subject: Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

Ref.: Scrip Code: 512600

Security Id: ASTALLTD

Respected Sir/Madam,

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

The aforesaid information is also available on the website of the Company <https://astallabs.com/>

Kindly acknowledge the receipt.

Thanking You,  
Yours Faithfully,

For Astal Laboratories Limited

*Mahendra*

Mahendra Kumar  
(Company Secretary & Compliance Officer)  
Membership No.: A71224







Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: 8-2-351/w/3/4, Road Number 3, Banjara Hills, Hyderabad, Telangana, 500034


SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: <https://astallabs.com/>

## STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR TO DATE FOR THE PERIOD ENDED DECEMBER 31, 2024

		Rs. (In Lakhs)					
Sr. No	Particulars	Quarter Ended	Preceding Quarter Ended	Corresponding Quarter Ended in Previous Year	9 Months Ended	Corresponding 9 Months Ended in Previous Year	Year ended
		31-12-24	30-09-24	31-12-23	31-12-24	31-12-23	31-03-24
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	<b>Revenue</b>						
	a) From operations	1,445.88	1,315.98	841.23	4,076.43	1,139.56	2,364.77
	b) Other Income (Refer to Note No.3)	5.59	0.00	-	9.01	1.20	1.34
	<b>Total Revenue</b>	<b>1,451.47</b>	<b>1,315.98</b>	<b>841.23</b>	<b>4,085.44</b>	<b>1,140.76</b>	<b>2,366.11</b>
2	<b>Expenses</b>						
	(a) Cost of Material Consumed	1,227.66	1,310.14	--	3,696.92	-	2,239.64
	(b) Purchases of stock-in-trade	-	-	769.87	-	1,058.66	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(194.42)	(360.40)	-	(721.01)	-	(105.76)
	(d) Employees Benefits expenses	40.67	43.34	4.74	124.77	7.57	46.57
	(e) Finance Cost	28.08	9.13	-	43.49	-	1.08
	(f) Depreciation amortization expenses	8.13	2.50	0.75	11.90	0.95	2.95
	(g) Other Expenses	39.57	34.00	17.14	116.47	20.84	72.97
	<b>Total Expenses</b>	<b>1,149.68</b>	<b>1,038.71</b>	<b>792.50</b>	<b>3,272.54</b>	<b>1,088.02</b>	<b>2,257.45</b>
3	<b>Profit from ordinary activities before exceptional</b>						
	<b>Items (1 - 2)</b>	<b>301.79</b>	<b>277.28</b>	<b>48.73</b>	<b>812.90</b>	<b>52.74</b>	<b>108.66</b>
4	<b>Exceptional Items - Income/ (Expenses)</b>	-	-	-	-	-	-
5	<b>Profit from ordinary activities before tax (3 - 4)</b>	<b>301.79</b>	<b>277.28</b>	<b>48.73</b>	<b>812.90</b>	<b>52.74</b>	<b>108.66</b>
6	<b>Tax Expenses</b>						
	(a) Current Tax	43.21	77.10	-	182.60		29.37

*Sudhey*







Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: 8-2-351/w/3/4, Road Number 3, Banjara Hills, Hyderabad, Telangana, 500034

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: meil100@rediffmail.com; Mob. No: 6302730973, Website: <https://astallabs.com/>

	(b) Deferred Tax	9.72	(0.12)		12.25		0.82
7	<b>Profit/(Loss) for the period (5 -6)</b>	248.86	200.29	48.73	618.05	52.74	78.47
8	A (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss (net of tax)	-	-	-	-	-	-
	(ii) Income Tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
9	<b>Total Comprehensive Income, net of tax (7 + 8)</b>	248.86	200.29	48.73	618.05	52.74	78.47
10	<b>Paid up equity share capital</b> (Face Value of Rs.10/- each)	984.56	984.56	493.96	984.56	493.96	984.56
11	<b>Earning Per share</b> (of Rs.10/- each) not annualised)						
	(a) Basic	2.528	2.040	1.015	6.277	1.241	1.554
	(b) Diluted	2.528	2.040	1.015	6.277	1.241	1.554

See accompanying notes to financial results

For ASTAL LABORATORIES LIMITED

SUDHEER KARNA KANKANALA

(Whole Time Director)

DIN: 07591466

Date :27/01/2025

Place: Hyderabad







Astal Laboratories Limited

# ASTAL LABORATORIES LIMITED

(Formerly known as MACRO INTERNATIONAL LIMITED)

CIN: L74120UP1993PLC015605

Regd. Office: Office No. B7, A-40, Sector 4, Noida, Gautam Buddha Nagar, Uttar Pradesh 201301

Corporate Office: 8-2-351/w/3/4, Road Number 3, Banjara Hills, Hyderabad, Telangana, 500034

SCRIP CODE: 512600, SECURITY ID: ASTALLTD, BSE India

Email: [meil100@rediffmail.com](mailto:meil100@rediffmail.com); Mob. No: 6302730973, Website: <https://astallabs.com/>

## NOTES:

1	The above Unaudited Financial Results of the company for the quarter ended December 31, 2024 have been reviewed by the Audit Committee and on its recommendation, have been approved by the Board of Directors at its meeting held on January 27, 2025.
2	The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs).
3	Figures in respect of the previous year/period have been rearranged /regrouped wherever necessary to correspond with the figures of the current year/period.
4	These financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act 2013 and other recognized accounting practices and policies to the extent possible and in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015 and SEBI Circular dated 5 July, 2016
5	The Name of the Company was changed due to change in the business activity of the Company. The company is required to include the turnover, income etc. from new activities separately in the quarterly/annual results for a period of 3 years from the date of change in name of the company. As the Company is carrying only one activity i.e. Present activity 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs). So, the turnover, income etc. from new activities not shown separately in the quarterly/annual results.
6	The Company has opted to publish the financial result. The standalone results of the company will be available on the company's website <a href="https://astallabs.com/">https://astallabs.com/</a>

For ASTAL LABORATORIES LIMITED


SUDHEER KARNA KANKANALA

(Whole Time Director)

DIN: 07591466

Date :27/01/2025

Place: Hyderabad





**Limited Review Report**

To  
Board of Directors  
**Astal Laboratories Limited**

We have reviewed the accompanying statement of Standalone unaudited quarterly financial results of **M/s Astal Laboratories Limited** for the quarter ended on 31<sup>st</sup> December, 2024, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligations & Disclosure Requirements) Regulation, 2015, (the Regulation) as amended, (the "Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We have conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.




Contd .... 2



:: 2 ::

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.


For Sathuluri & Co  
Chartered Accountants  
Firm Reg No.006383S



(S.S.Prakash)

Partner

Membership No.202710



UDIN : 25202710BMKWXN2929

Place: Hyderabad

Date: 27-01-2025



**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

<b>Statement on deviation / variation in utilization of funds raised by issue of Convertible warrants through Preferential Issue</b>	
Name of listed entity	Astal Laboratories Limited Formerly known as Macro International limited
Mode of Fund Raising	Public Issues / Rights Issues / Preferential Issue / QIP / Others
Date of Raising Funds	27/11/2024
Amount Raised	37,299,300.00/-
Report filed for Quarter ended	31-12-2024
Monitoring Agency	N.A.
Monitoring Agency Name, if applicable	N.A.
Is there a Deviation /Variation in use of funds raised	N.A.
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	N.A.
Explanation for the Deviation I Variation	N.A.
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments
Objects for which funds have been raised and where there has been a deviation, in the following table	

<b>Original Object</b>	<b>Modified Object, if Any</b>	<b>Original Allocation</b>	<b>Modified allocation, if any</b>	<b>Funds Utilised</b>	<b>Amount of Deviation/Variation for the quarter according to applicable object</b>	<b>Remark</b>
To Meet the working capital requirements and general corporate purposes in order to support the future growth	N.A.	Rs. 37,299,300.00/-	NIL	Rs. 37,299,300.00/-	NIL	N.A.

*Mahendra*





plan of the Company						
---------------------	--	--	--	--	--	--

**C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES- – Not Applicable.**

**D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – Not Applicable.**

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) – Not Applicable.**

